AstraZeneca PLC (AZN) EV/EBIT Ratio: 21.72x
Is AstraZeneca PLC’s EV/EBIT ratio high or low?
AstraZeneca PLC's EV/EBIT ratio of 21.72x is 94% below its 5-year average of 345.83x, near the low end of its 5-year range (21.06x–6316.10x).
As of Friday, June 12, 2026. 9.14% below its 12-month average of 23.90x.
AZN EV/EBIT Ratio Chart
AZN Average EV/EBIT Ratio Chart
AZN Current vs Average EV/EBIT Ratio Chart
AZN EV/EBIT Ratio Metrics
EV/EBIT RATIO
21.72x
EV/EBIT RATIO AVG TTM
23.90x
EV/EBIT RATIO AVG 3Y
26.95x
EV/EBIT RATIO AVG 5Y
345.83x
EV/EBIT RATIO AVG 10Y
184.23x
EV/EBIT RATIO AVG 15Y
128.66x
EV/EBIT RATIO AVG 20Y
98.03x
CURRENT VS TTM AVG
-9.14%
CURRENT VS 3Y AVG
-19.40%
CURRENT VS 5Y AVG
-93.72%
CURRENT VS 10Y AVG
-88.21%
CURRENT VS 15Y AVG
-83.12%
CURRENT VS 20Y AVG
-77.84%
AZN Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AstraZeneca PLC (AZN) | $282.69B | 21.72x | 23.90x | 26.95x | 345.83x |
| Merck & Co., Inc. (MRK) | $298.29B | 18.91x | 12.24x | 31.15x | 27.84x |
| UnitedHealth Group Incorporated (UNH) | $368.30B | 22.24x | 13.82x | 15.44x | 17.15x |
| Amgen Inc. (AMGN) | $191.09B | 20.20x | 24.76x | 26.21x | 23.36x |
| Thermo Fisher Scientific Inc. (TMO) | $176.77B | 27.08x | 28.28x | 30.55x | 28.32x |
| AbbVie Inc. (ABBV) | $397.12B | 26.65x | 39.30x | 31.81x | 26.56x |
| Gilead Sciences, Inc. (GILD) | $156.28B | 15.15x | 18.28x | 42.67x | 31.51x |
| Abbott Laboratories (ABT) | $156.15B | 22.42x | 27.94x | 30.32x | 27.86x |
| Pfizer Inc. (PFE) | $149.18B | 14.33x | 12.24x | 29.84x | 23.37x |
| Intuitive Surgical, Inc. (ISRG) | $146.23B | 45.47x | 63.12x | 72.98x | 67.74x |
AstraZeneca PLC EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AstraZeneca PLC EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for AstraZeneca PLC (AZN)?
- The EV/EBIT ratio for AZN stock is 21.72x.
- Is AstraZeneca PLC's EV/EBIT ratio high or low?
- AstraZeneca PLC's EV/EBIT ratio of 21.72x is 94% below its 5-year average of 345.83x, near the low end of its 5-year range (21.06x–6316.10x).
- What is the TTM average EV/EBIT ratio for AstraZeneca PLC (AZN)?
- The TTM average EV/EBIT ratio for AZN stock is 23.90x.
- What is the 3Y average EV/EBIT ratio for AstraZeneca PLC (AZN)?
- The 3Y average EV/EBIT ratio for AZN stock is 26.95x.
- What is the 5Y average EV/EBIT ratio for AstraZeneca PLC (AZN)?
- The 5Y average EV/EBIT ratio for AZN stock is 345.83x.
- What is the 10Y average EV/EBIT ratio for AstraZeneca PLC (AZN)?
- The 10Y average EV/EBIT ratio for AZN stock is 184.23x.
- What is the 15Y average EV/EBIT ratio for AstraZeneca PLC (AZN)?
- The 15Y average EV/EBIT ratio for AZN stock is 128.66x.
- What is the 20Y average EV/EBIT ratio for AstraZeneca PLC (AZN)?
- The 20Y average EV/EBIT ratio for AZN stock is 98.03x.
AstraZeneca PLC EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-11 | 21.72x |
| 2026-06-10 | 21.36x |
| 2026-06-09 | 21.84x |
| 2026-06-08 | 21.64x |
| 2026-06-05 | 22.12x |
| 2026-06-04 | 21.67x |
| 2026-06-03 | 21.06x |
| 2026-06-02 | 21.19x |
| 2026-06-01 | 21.44x |
| 2026-05-29 | 22.09x |
| 2026-05-28 | 22.05x |
| 2026-05-27 | 22.09x |
| 2026-05-26 | 22.25x |
| 2026-05-22 | 22.24x |
| 2026-05-21 | 22.53x |
| 2026-05-20 | 22.28x |
| 2026-05-19 | 21.98x |
| 2026-05-18 | 21.90x |
| 2026-05-15 | 21.64x |
| 2026-05-14 | 22.01x |
| 2026-05-13 | 22.31x |
| 2026-05-12 | 21.96x |
| 2026-05-11 | 21.67x |
| 2026-05-08 | 21.78x |
| 2026-05-07 | 21.74x |
| 2026-05-06 | 22.01x |
| 2026-05-05 | 21.60x |
| 2026-05-04 | 21.85x |
| 2026-05-01 | 21.99x |
| 2026-04-30 | 22.27x |
| 2026-04-29 | 22.04x |
| 2026-04-28 | 22.96x |
| 2026-04-27 | 23.06x |
| 2026-04-24 | 23.31x |
| 2026-04-23 | 23.60x |
| 2026-04-22 | 23.89x |
| 2026-04-21 | 24.00x |
| 2026-04-20 | 24.56x |
| 2026-04-17 | 25.02x |
| 2026-04-16 | 24.53x |
| 2026-04-15 | 24.61x |
| 2026-04-14 | 24.98x |
| 2026-04-13 | 24.73x |
| 2026-04-10 | 24.94x |
| 2026-04-09 | 25.04x |
| 2026-04-08 | 24.96x |
| 2026-04-07 | 24.57x |
| 2026-04-06 | 24.80x |
| 2026-04-02 | 24.87x |
| 2026-04-01 | 24.56x |
| 2026-03-31 | 24.16x |
| 2026-03-30 | 23.78x |
| 2026-03-27 | 23.16x |
| 2026-03-26 | 22.59x |
| 2026-03-25 | 23.02x |
| 2026-03-24 | 22.86x |
| 2026-03-23 | 22.67x |
| 2026-03-20 | 22.61x |
| 2026-03-19 | 23.22x |
| 2026-03-18 | 23.16x |
| 2026-03-17 | 23.49x |
| 2026-03-16 | 23.57x |
| 2026-03-13 | 23.33x |
| 2026-03-12 | 23.62x |
| 2026-03-11 | 23.72x |
| 2026-03-10 | 23.91x |
| 2026-03-09 | 23.90x |
| 2026-03-06 | 23.82x |
| 2026-03-05 | 24.20x |
| 2026-03-04 | 24.65x |
| 2026-03-03 | 24.68x |
| 2026-03-02 | 24.90x |
| 2026-02-27 | 25.44x |
| 2026-02-26 | 24.93x |
| 2026-02-25 | 25.14x |
| 2026-02-24 | 25.23x |
| 2026-02-23 | 26.91x |
| 2026-02-20 | 26.82x |
| 2026-02-19 | 27.36x |
| 2026-02-18 | 27.36x |
| 2026-02-17 | 27.46x |
| 2026-02-13 | 26.98x |
| 2026-02-12 | 26.86x |
| 2026-02-11 | 26.88x |
| 2026-02-10 | 25.46x |
| 2026-02-09 | 24.84x |
| 2026-02-06 | 25.45x |
| 2026-02-05 | 24.74x |
| 2026-02-04 | 24.77x |
| 2026-02-03 | 24.39x |
| 2026-02-02 | 24.89x |
| 2026-01-30 | 24.73x |
| 2026-01-29 | 24.25x |
| 2026-01-28 | 24.82x |
| 2026-01-27 | 24.85x |
| 2026-01-26 | 23.75x |
| 2026-01-23 | 23.56x |
| 2026-01-22 | 23.80x |
| 2026-01-21 | 23.26x |
| 2026-01-20 | 24.26x |
| 2026-01-16 | 25.22x |
| 2026-01-15 | 24.94x |
| 2026-01-14 | 25.11x |
| 2026-01-13 | 24.92x |
| 2026-01-12 | 24.53x |
| 2026-01-09 | 25.21x |
| 2026-01-08 | 24.90x |
| 2026-01-07 | 25.18x |
| 2026-01-06 | 25.14x |
| 2026-01-05 | 23.75x |
| 2026-01-02 | 24.19x |
| 2025-12-31 | 23.32x |
| 2025-12-30 | 23.97x |
| 2025-12-29 | 24.73x |
| 2025-12-26 | 24.02x |
| 2025-12-24 | 24.65x |
| 2025-12-23 | 24.23x |
| 2025-12-22 | 23.96x |
| 2025-12-19 | 24.02x |
| 2025-12-18 | 23.93x |
| 2025-12-17 | 24.44x |
| 2025-12-16 | 24.19x |
| 2025-12-15 | 24.34x |
| 2025-12-12 | 23.82x |
| 2025-12-11 | 23.94x |
| 2025-12-10 | 24.10x |
| 2025-12-09 | 23.76x |
| 2025-12-08 | 23.98x |
| 2025-12-05 | 23.80x |
| 2025-12-04 | 23.87x |
| 2025-12-03 | 24.27x |
| 2025-12-02 | 23.76x |
| 2025-12-01 | 23.91x |
| 2025-11-28 | 24.32x |
| 2025-11-26 | 24.90x |
| 2025-11-25 | 24.81x |
| 2025-11-24 | 24.19x |
| 2025-11-21 | 24.18x |
| 2025-11-20 | 23.60x |
| 2025-11-19 | 23.84x |
| 2025-11-18 | 23.28x |
| 2025-11-17 | 23.29x |
| 2025-11-14 | 23.23x |
| 2025-11-13 | 23.56x |
| 2025-11-12 | 23.34x |
| 2025-11-11 | 23.28x |
| 2025-11-10 | 23.24x |
| 2025-11-07 | 22.18x |
| 2025-11-06 | 22.52x |
| 2025-11-05 | 24.62x |
| 2025-11-04 | 25.03x |
| 2025-11-03 | 24.57x |
| 2025-10-31 | 24.97x |
| 2025-10-30 | 24.95x |
| 2025-10-29 | 24.81x |
| 2025-10-28 | 25.07x |
| 2025-10-27 | 24.85x |
| 2025-10-24 | 24.82x |
| 2025-10-23 | 25.44x |
| 2025-10-22 | 25.25x |
| 2025-10-21 | 25.44x |
| 2025-10-20 | 25.27x |
| 2025-10-17 | 25.80x |
| 2025-10-16 | 25.56x |
| 2025-10-15 | 25.42x |
| 2025-10-14 | 25.56x |
| 2025-10-13 | 25.55x |
| 2025-10-10 | 25.59x |
| 2025-10-09 | 25.66x |
| 2025-10-08 | 25.97x |
| 2025-10-07 | 25.68x |
| 2025-10-06 | 26.00x |
| 2025-10-03 | 25.75x |
| 2025-10-02 | 24.95x |
| 2025-10-01 | 24.66x |
| 2025-09-30 | 22.86x |
| 2025-09-29 | 22.39x |
| 2025-09-26 | 22.40x |
| 2025-09-25 | 22.89x |
| 2025-09-24 | 22.80x |
| 2025-09-23 | 23.03x |
| 2025-09-22 | 23.87x |
| 2025-09-19 | 23.53x |
| 2025-09-18 | 23.39x |
| 2025-09-17 | 23.76x |
| 2025-09-16 | 23.34x |
| 2025-09-15 | 23.56x |
| 2025-09-12 | 24.24x |
| 2025-09-11 | 24.58x |
| 2025-09-10 | 24.32x |
| 2025-09-09 | 24.38x |
| 2025-09-08 | 24.73x |
| 2025-09-05 | 24.92x |
| 2025-09-04 | 24.58x |
| 2025-09-03 | 24.62x |
| 2025-09-02 | 24.40x |
| 2025-08-29 | 24.46x |
| 2025-08-28 | 24.06x |
| 2025-08-27 | 24.39x |
| 2025-08-26 | 24.35x |
| 2025-08-25 | 24.71x |
| 2025-08-22 | 23.90x |
| 2025-08-21 | 24.43x |
| 2025-08-20 | 24.00x |
| 2025-08-19 | 24.18x |
| 2025-08-18 | 24.37x |
| 2025-08-15 | 23.68x |
| 2025-08-14 | 23.72x |
| 2025-08-13 | 23.52x |
| 2025-08-12 | 22.69x |
| 2025-08-11 | 22.39x |
| 2025-08-08 | 21.79x |
| 2025-08-07 | 22.55x |
| 2025-08-06 | 22.75x |
| 2025-08-05 | 22.97x |
| 2025-08-04 | 22.97x |
| 2025-08-01 | 22.58x |
| 2025-07-31 | 22.57x |
| 2025-07-30 | 23.71x |
| 2025-07-29 | 22.99x |
| 2025-07-28 | 23.80x |
| 2025-07-25 | 23.99x |
| 2025-07-24 | 24.22x |
| 2025-07-23 | 24.28x |
| 2025-07-22 | 23.48x |
| 2025-07-21 | 23.15x |
| 2025-07-18 | 22.84x |
| 2025-07-17 | 22.98x |
| 2025-07-16 | 23.50x |
| 2025-07-15 | 23.26x |
| 2025-07-14 | 23.66x |
| 2025-07-11 | 23.24x |
| 2025-07-10 | 23.73x |
| 2025-07-09 | 23.41x |
| 2025-07-08 | 23.22x |
| 2025-07-07 | 23.59x |
| 2025-07-03 | 23.30x |
| 2025-07-02 | 23.77x |
| 2025-07-01 | 23.16x |
| 2025-06-30 | 23.16x |
| 2025-06-27 | 22.93x |
| 2025-06-26 | 23.19x |
| 2025-06-25 | 24.12x |
| 2025-06-24 | 23.36x |
| 2025-06-23 | 23.50x |
| 2025-06-20 | 23.15x |
| 2025-06-18 | 23.73x |
| 2025-06-17 | 23.34x |
| 2025-06-16 | 24.43x |
| 2025-06-13 | 24.39x |
| 2025-06-12 | 24.69x |
| 2025-06-11 | 24.41x |
| 2025-06-10 | 24.18x |
| 2025-06-09 | 24.16x |
| 2025-06-06 | 23.84x |
| 2025-06-05 | 23.61x |
| 2025-06-04 | 24.03x |
| 2025-06-03 | 23.57x |
| 2025-06-02 | 23.57x |
| 2025-05-30 | 23.42x |
Showing the most recent 260 of 4,968 data points. The chart above shows the full history.
Related Metrics
About AstraZeneca PLC
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Pascal Claude Roland Soriot